28 articles found
Virginia, Shatterproof and 211 Virginia launched Treatment Atlas, a free platform that compares addiction programs on evidence-based care, insurance and medications.
Brellium, whose AI reads clinical notes for mental health and autism providers, raised $23 million to push into pain management and primary care.
NYC Mental Health Connect, funded with $5 million from New York State, lets residents search more than 600 behavioral health providers by insurance and language.
A Bronx trial's automated opioid-use screen flagged 9,140 records but produced just 23 buprenorphine starts, a 5 percent initiation rate.
Pennsylvania expects $516 million to $729 million from a Meta child-safety settlement, but lawmakers and the attorney general disagree over who controls the money.
Gov. Gavin Newsom vetoed Senate Bill 903, which would have barred companies from offering or advertising chatbot-delivered therapy to Californians.
A federal class action filed in Boston alleges DraftKings used machine learning to single out gamblers likely to lose more and then target them with promotions.
NET Recovery's wearable neurostimulation device receives FDA Breakthrough Device Designation for stimulant addiction, where no drug or device is currently approved.
Nature Communications publishes breakthrough wireless microneedle device that delivers electrical stimulation for pain relief, offering non-opioid alternative for chronic pain management.
Arizona's Medicaid agency AHCCCS debuts a GenAI locator built on Google's Gemini that connects residents to more than 100 vetted opioid treatment providers.
The Department of Veterans Affairs is expanding FDA-authorized virtual reality therapy to treat chronic pain in veterans, offering an eight-week home-based program that reduces reliance on opioids.
Phase 3 trial shows Eli Lilly's oral GLP-1 drug orforglipron delivers superior blood sugar control and weight loss compared to oral semaglutide.
DyAnsys Drug Relief receives FDA clearance as a non-narcotic auricular neurostimulation device designed to alleviate opioid withdrawal symptoms during detoxification.
Aptihealth settles for $300,000 after billing Medicaid for no-show appointments as DOJ charges 455 defendants in $6.5 billion health care fraud crackdown targeting telehealth sector.
New FAIR Health data reveals mental health conditions account for 52% of all telehealth diagnoses in Q1 2026, ranking as the top diagnostic category in every U.S. region and every age group including children under 10.
Landmark BMJ study of 600,000+ veterans finds GLP-1 medications like Ozempic and Wegovy associated with 14-25% lower risk of developing substance use disorders, including alcohol, opioids, and stimulants.
Comprehensive Healthcare in Yakima implements ZING robotic dosing system, reducing wait times and improving accuracy for medication-assisted treatment patients in rural Washington.
New research demonstrates that VR-based cue exposure therapy can effectively reduce cravings in people with substance use disorders, offering a scalable digital health intervention.
Machine learning models analyzing electronic health records can identify patients at high risk of fatal overdose up to 12 months before the event, offering a new tool for preventive intervention.
Mississippi State Department of Health scales innovative addiction treatment program statewide using Epic EHR technology to identify risk earlier and reduce barriers to care in rural communities.
Trump administration proposes national wastewater monitoring and artificial intelligence to track drug use patterns, alongside faith-based treatment expansion and integrated addiction care.
Researchers analyze 569,000 TikTok comments to demonstrate social media data can forecast synthetic opioid mortality with 37% greater accuracy than traditional surveillance methods.
New Mexico becomes testing ground for SAMHSA-vetted digital recovery platform with dedicated teen version, offering 24/7 peer support and crisis intervention through smartphones.
Workit Health's evidence-based virtual care model delivers 62% rural retention at three months—more than double competing programs—with peer-reviewed studies in JAMA Network Open showing perfect buprenorphine adherence among participants.
New study finds NET Device reduces opioid and stimulant use for 3 months post-treatment, offering hope for polysubstance addiction amid no approved medications for stimulants
Washington University research shows uMAT-R app reduced opioid and drug use by 50% in people experiencing housing insecurity, addressing critical gap in treatment access.
Digital therapeutics for substance use disorders are gaining traction as researchers identify key strategies to improve engagement and outcomes, with apps reaching patients beyond traditional clinic walls.
Washington University study finds that uMAT-R digital platform reduced substance use by 50% among participants with housing instability, challenging assumptions about technology access in vulnerable populations.